
Marksans Pharma Limited has informed the Exchange regarding a press release dated August 18, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for its products.".
Filed with NSE ·

Marksans Pharma Limited has informed the Exchange regarding a press release dated August 18, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for its products.".
6ix hasn’t read this filing yet.
Marksans Pharma Limited on 6ix
Follow Marksans Pharma into a list and get an email when it puts out news.
Follow Marksans Pharma